We have a seasoned management team that has brought 30+ innovative therapeutic agents from early-phase development to the global market. Our team possesses deep scientific, clinical, regulatory, operational and financial expertise in both the U.S. and China, which optimally positions BeyondSpring to accomplish its near- and long-term objectives.
Lan Huang, Ph.D.
Co-founder, Chairman & Chief Executive Officer
Dr. Huang has more than a decade of entrepreneurial experience in the Chinese and U.S. biotechnology industry. She has invented and holds patents for a number of biotech products for oncology and dermatology indications.
Prior to founding BeyondSpring, Dr. Huang co-founded Wuxi MTLH Biotechnology Co. Ltd., whose self-designed cancer peptide drug’s China rights were acquired in 2010 by Shanghai Pharmaceutical Group, one of the top three pharmaceutical companies in China. She also co-founded Paramax International, a clinical CRO company in China, which was sold to RPS (a global CRO), then to Warburg Pincus in 2011. In addition, Dr. Huang worked with Forward Ventures, where she led partnering initiatives between Forward’s portfolio companies and Chinese pharmaceutical companies.
Dr. Huang was trained at Memorial Sloan Kettering Cancer Center, where her breakthrough research in solving the first E2-E3 ubiquitin ligase structure involving P53 degradation was published in Science following 10 months of preparation. The immense importance of this field is illustrated by the 2005 award of the Nobel Prize in Chemistry to the founders of ubiquitin-mediated protein degradation. She received her Ph.D. in Chemistry in four-and-a-half years from the University of California at Berkeley, where she won the graduating Ph.D. woman award from Soroptimist International. Her translational research in cancer signaling pathways involving Ras was published in two Nature papers.
Dr. Huang received her B.A., Magna Cum Laude and Phi Beta Kappa, from Lawrence University, where she served as a trustee. She also studied at Fudan University in Shanghai, China.
Ramon Mohanlal, M.D., Ph.D.
EVP, Research and Development
Chief Medical Officer
Dr. Mohanlal has more than 20 years of global experience in strategic drug development at big pharma, and biotech start-ups, including GlaxoWellcome (GSK), Pharmacia (Pfizer), Vertex, Interleukin Genetics, Syntium, Novartis, and AstraZeneca. His expertise includes drug development in all Phases (preclinical and 1, 2, 3, 4 clinical, post-marketing), regulatory filings and maintaining drugs on the market.
Dr. Mohanlal played a crucial role in bringing five drugs to market and was deeply involved in the development of 15 marketed drugs, including Wellferon, Atovaquone, Lamuvidine, Zomig, Advexin, Abilify IM Depot, Zometa, Femara, Aredia, Proleukin, Cardioxane and Exjade. Most recently, Dr. Mohanlal was the Clinical Head of Established Oncology Products for Novartis, where he managed all clinical and regulatory maintenance work for the division, which represented total annual revenue of approximately $2 billion. He also developed immuno-oncology development programs based on checkpoint inhibitor combination therapy at AstraZeneca. Prior to this, Dr. Mohanlal held positions with Interleukin Genetics as Chief Medical Officer and Vertex Pharmaceuticals as Medical Director. Dr. Mohanlal has also obtained extensive licensing and deal-making experience at Syntium Inc.
Dr. Mohanlal earned his M.D. and Ph.D. in Experimental CV Pharmacology, both from the University of Leiden, The Netherlands, as well as his M.B.A. from the American Intercontinental University in Illinois, with post-graduate business training at the MIT Sloan School of Management, Cambridge, Massachusetts.
Richard J. Daly
Chief Operating Officer
Mr. Daly joins the Company with more than 25 years of experience heading business and commercial operations for leading pharmaceutical and biotech companies, including as Executive Vice President at Takeda Pharmaceuticals U.S. and as President of AstraZeneca’s U.S. Diabetes subsidiary. Most recently, Mr. Daly served as CEO, President and Chairman of Neuralstem, Inc. Mr. Daly currently serves on the boards of Catalyst Pharmaceuticals and Opiant Pharmaceuticals.
Mr. Daly was instrumental in building Takeda North America from 14 people to more than 3,000 employees and $5 billion in sales in less than seven years. During his 13-year tenure, he served as Executive Vice President, U.S., where he was responsible for business development for the Americas and for expanding the company’s commercial footprint across North and South America and into new therapeutic areas including oncology. As President of AstraZeneca’s U.S. Diabetes subsidiary, Mr. Daly led commercial initiatives that transformed the Bristol-Myers Squibb and AstraZeneca Diabetes Alliance into the fastest-growing diabetes franchise in the U.S. in less than 12 months.
Mr. Daly earned an MBA from Northwestern University’s Kellogg School of Management and holds a B.S. in microbiology from University of Notre Dame.
G. Kenneth Lloyd, Ph.D.
Chief Scientific Officer
Dr. Lloyd has more than 45 years of experience in the pharmaceutical industry, with a focus on novel drug discovery and development, working in both large pharma (F. Hoffman LaRoche, Synthelabo and Wyeth Ayerst) and start-up biotechs (SIBIA, Nereus).
Previous positions include Vice-Director at Synthelabo (now Sanofi), Director of Research at Wyeth U.K. and Chief Scientific Officer at Nereus Pharmaceuticals, where he was responsible for the discovery, selection and development of Plinabulin. In addition to Plinabulin, Dr. Lloyd has led the development of marizomib (proteasome inhibitor for multiple myeloma), progabide and the discovery and early development of zolpidem.
Dr. Lloyd received his undergraduate education and M.S. in Biochemistry at McGill University and Ph.D. in Pharmacology and Toxicology from the University of Toronto, followed by a post-doctoral fellowship at F. Hoffmann LaRoche in Basel. He has more than 300 publications in journals that include Science, Nature and the New England Journal of Medicine.
Gordon L. Schooley, Ph.D.
Chief Regulatory Officer
Dr. Schooley has 35 years of experience in the pharmaceutical industry, with a focus on clinical and regulatory affairs, and he has been associated with product development and approvals of 19 marketed drugs in the U.S., Europe and Pacific Rim countries.
Previous positions include Director of Clinical Research at Allergan, V.P. of Clinical Research & Regulatory Affairs at Newport Pharmaceuticals International, V.P. of Clinical Research & Regulatory Affairs at Alliance Pharmaceutical Corp. and CSO and Senior V.P. of Clinical Development & Regulatory Affairs at Skye Pharma-Pacira Pharmaceuticals. He has participated in multiple product approvals in the U.S., Canada, Australia and Europe, including those for DepoCyte, 5-flurouracil, Solarize and Alprazolam. He also has experience in oncology, including hepatic carcinoma, neoplastic meningitis and glioblastoma.
Dr. Schooley received his undergraduate training and M.S. at Brigham Young University and Ph.D. in Biostatistics and Medical Care Organization & Administration at the University of Michigan, School of Public Health.
Edward Dongheng Liu
Chief Financial Officer
Edward Dongheng Liu joins BeyondSpring with more than a decade of investment banking and investment experience in the Asia-Pacific region.
Prior to joining BeyondSpring, Mr. Liu was a Partner and Executive Director at Epiphron Capital, a cross-border, healthcare-focused investment fund that was an early investor in BeyondSpring. Prior to that, he held various leadership positions in the investment banking industry based in Hong Kong focusing on clients in the Asia-Pacific region. He was a Senior Vice President and Vice President at Investment Banking and Capital Markets at Jefferies. Prior to Jefferies, he held various roles of increasing responsibilities at Investment Banking Division at J.P. Morgan. As an investment banker, Mr. Liu has led financing and M&A transactions for clients across sectors with a total transaction value exceeding US$30 billion.
Mr. Liu received his bachelor’s degree in economics and mathematics from Yale University. He also completed biomedical engineering coursework at Tsinghua University.
James R. Tonra, Ph.D.
SVP, Preclinical Development
After earning a doctorate in Physiology and Biophysics, James R. Tonra, Ph.D. has worked for over 20 years in biotechnology, leading and utilizing in-house, contracted and sponsored research efforts to generate definitive data packages that enable the prioritization of research projects and guide clinical development at Regeneron Pharmaceuticals, Millennium Pharmaceuticals, ImClone Systems/Eli Lilly, and Kadmon Holdings.
Dr. Tonra has collaborated with and lead multidisciplinary teams to develop biologic and small molecule drug candidates for disease indications including inflammation, oncology, diabetes, and CNS disorders. He has authored over 40 peer-reviewed publications and is an inventor on numerous use-patents. At ImClone Systems, prior to the successful acquisition by Eli Lilly, Dr. Tonra’s efforts significantly contributed to the IND filing and clinical strategy development for 8 novel drugs, 3 of which are now approved therapies for cancer: Cyramza, Portrazza and Lartruvo.
Dr. Tonra received his Ph.D. in Physiology and Biophysics from SUNY at Stony Brook and B.S. in Physics, Summa Cum Laude, from SUNY at Stony Brook.